We warmly invite everyone in the Cancer Commons community to an afternoon of lovely and lively music on Sunday June 9, in Los Altos, CA. Organized by our very own Masako Yokota, a cancer survivor and classically trained vocalist, the concert will feature a selection of tunes by renowned American composer George Gershwin. Ms. Yokota will be joined by local pianist and accompanist David Stein; together, they will perform a delightful program of Gershwin’s classical compositions and American songs.
All proceeds from the concert will go to Cancer Commons, which aims to connect patients and their physicians with the knowledge they need to achieve the best possible outcomes, help them access relevant treatments and trials, and continuously learn from their experiences. We hope you will join us for a wonderful afternoon of music while supporting this important cause!
When: Sunday, June 9, 3:30 to 5:00 pm Where: Bridges Community Church, 625 Magdalena Ave, Los Altos, CA 94024 Suggested donation: $20 More info:email@example.com
Gershwin photo (left) from George Grantham Bain collection, Library of Congress
“Big data and machine learning have the potential to improve health, detecting disease at an earlier stage and personalizing interventions. The key ingredient, some say, is applying algorithms to population-wide datasets. But the question remains: is it enough to train smarter algorithms with broader datasets? What other approaches, diagnostics tools, and technologies do we need to accurately assess a patient’s unique needs and build a personalized intervention? A panel of experts across diagnostics, informatics, and therapeutics from government, academia, integrated health centers, data science, and biopharma will lead a highly interactive exploration of these issues and predict what it will take to realize the role of data science enabling personalized medicine.”
Cancer Commons founder Marty Tenenbaum, PhD, will speak at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative at the National Academy of Sciences in Washington, DC, on March 4 at 5:00 pm. Marty, who founded Cancer Commons after his own battle with melanoma, will facilitate an expert panel discussion on “Reinventing Clinical Research and Cancer Care.” That same day, he will also lead a lunchtime discussion on “Shifting the Clinical Trials Paradigm From Approving Drugs to Curing Patients.”
In preparation for the conference, Marty has written a piece for Bridging Clinical that outlines his take on the increasing demand for patients in clinical research. An excerpt: “Those familiar with the current drug development process express skepticism that the system can ever be changed — and for good reason; many have tried and failed. However, a confluence of trends, from patient activism to the explosion of new therapies to an unprecedented open regulatory environment, make a paradigm shift from drug-developer-centric to patient-centric trials both necessary and possible.” Click here to read the full article.
Cancer Commons leadership, including founder Marty Tenenbaum, executive director Erika Vial Monteverdi, and editor in chief George Lundberg, are speaking at the 2019 Precision Medicine World Conference (PMWC) in Silicon Valley. Every year, the conference attracts doctors, innovators, and patients “to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.”
On January 22 at 8:45 am, Marty will lead a panel discussing the potential of real-world evidence to inform research and clinical decision making: “Traditionally, the majority of evidence regarding the benefits and risks of cancer treatments is derived from clinical trial populations. However, the vast majority of cancer patients receive treatment outside the context of clinical trials. There is tremendous motivation to evaluate the benefits and risks of cancer treatments delivered in the context of ‘real world’ care. Real-world evidence (RWE) is typically defined as treatment that is not delivered in accordance with an investigational protocol and therefore lacks clearly specified endpoints and assessment intervals for determining benefit. This session will cover opportunities and challenges in using real-world evidence to inform clinical decision making in cancer. The session will review opportunities and challenges in defining real world endpoints and the development of methods and analytical tools capable of generating insights from RWE.” Continue reading…
Cancer Commons founder Marty Tenenbaum, PhD, will speak at the NYC Oncology Investor Conference on October 30. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
Read the synopsis of Marty’s presentation, “Can AI Cure Cancer?”: No one knows the optimal way to treat any cancer with currently available therapies. When clinical advances are made, it can take years for you and your doctor to find out about them. Getting access to breakthrough therapies, in a clinical trial or through expanded access, is problematic. Developing a new drug from scratch can take a decade or more and cost upwards of a billion dollars. AI can help. I will outline a plan, with the potential to save many thousands of lives, and a strategy for funding it through philanthropy and impact investing.
The NYC Oncology Investor Conference brings together “leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak May 11 at the Stanford AI Salon, a regular event hosted by the Stanford University Artificial Intelligence Laboratory. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments in a talk titled “How can AI cure cancer?”
According to the event website, “AI Salon is a roughly bi-weekly event on Fridays where the AI Lab gathers to discuss high-level topics in AI and machine learning. The goal is to encourage ourselves to think beyond our individual day-to-day research, and better see how our work fits into the long-term trajectory of scientific progress, and into society as a whole. Each Salon has a different topic for discussion, which is led by two speakers: typically one expert guest, and one AI Lab member. We hold the event in the spirit of Enlightenment-era salons, with no electronics or whiteboard allowed: only free-ranging discussion among attendees, starting with a 10-minute opening statement from the two speakers.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Bio-IT World Conference & Expo in Boston, which runs May 15 to 18. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
AI can beat go and drive cars, but can it beat cancer? Every year, many thousands of cancer patients die unnecessarily because their doctors do not know the optimal way to treat them with currently available therapies. Physicians and patients alike struggle with information overload and conflicting expert opinions in making treatment decisions. Moreover, effective treatments increasingly involve intelligently designed, individually tailored, sequences and combinations, and there are far more plausible multi-drug regimens than can be efficiently tested in clinical trials. AI can help by connecting physicians and patients to the right information at the right time, and by planning and coordinating the thousands of formal and informal treatment experiments that take place daily in oncology, to optimize individual outcomes and maximize collective knowledge. We will describe a developing global collaboration to realize this bold vision, involving leading oncologists, cancer and data scientists, and AI experts from both academia and industry, and discuss opportunities for all to participate.
The Bridging Clinical Research & Clinical Health Care Collaborative is “the only forum where clinical research and health care professionals come together to envision a collaborative solution that strengthens the connection between clinical research and health care.” Learn more about the event at https://www.bridgingclinical.com/agenda/.
A little more than four years ago, longtime friends Tom and Carman Duvall, and Kiers and Steve Rowley reminisced at dinner about their lives in the 1980s, long before their schedules had grown complicated and filled with endless trips driving children to various activities.
Tom, a child of 1980s rock and roll, wondered aloud whether Def Leppard might perform for them on his next birthday. Conversation meandered during the evening, and when the check arrived, Tom and Steve advised Kiers and Carman that a date had been set for a rock concert on the Duvall property in Independence, Missouri, and that it would be a fundraising event to support patients suffering with cancer. Kiers, who’d struggled with lung cancer for the past five years, and Carman announced “We’re in.” So began an all-day-long summer music festival and tradition resembling Woodstock, that the four friends named Tomstock. Continue reading…